Current aspects of the epidemiology and treatment of chronic brain ischemiain the presence of essential hypertension (results of the CALIPSO program)
Abstract
The paper gives the results of the multicenter clinical and epidemiological program CALIPSO (Cavinton in the treatment of patients with
chronic cerebral circulatory disorder: dyscirculatory encephalopathy in the presence of essential hypertension). The program covered 4865
patients with chronic hypertension-related cerebrovascular insufficiency from 42 cities and towns of the Russian Federation. The patients
received dropwise intravenous Cavinton as infusions within the first week (25 mg on days 1 to 4 and 50 mg on days 5 to 7) then oral Cavinton
forte, 30 mg/day, for 90 days. Therapy with Cavinton and Cavinton forte led to improvements in health, balance (the Tinnetti scale), and
cognitive functions (the mini mental state examination). This study has provided evidence for the safety of Cavinton.
chronic cerebral circulatory disorder: dyscirculatory encephalopathy in the presence of essential hypertension). The program covered 4865
patients with chronic hypertension-related cerebrovascular insufficiency from 42 cities and towns of the Russian Federation. The patients
received dropwise intravenous Cavinton as infusions within the first week (25 mg on days 1 to 4 and 50 mg on days 5 to 7) then oral Cavinton
forte, 30 mg/day, for 90 days. Therapy with Cavinton and Cavinton forte led to improvements in health, balance (the Tinnetti scale), and
cognitive functions (the mini mental state examination). This study has provided evidence for the safety of Cavinton.
References
1. <div><p>Инсульт: диагностика, лечение, профилактика. Под ред. З.А. Суслиной, М.А. Пирадова. М.: МЕДпресс-информ, 2009;288 с.</p><p>Гусев Е.И., Скворцова В.И., Стаховская Л.В. и др. Эпидемиология инсульта в России. Consilium medicum (спецвыпуск) 2003;5-7.</p><p>Скворцова В.И. Снижение заболеваемости, смертности и инвалидности от инсультов в Российской Федерации. Журн неврол и психиатр им С.С. Корсакова. Инсульт (прил.) 2007;25-31.</p><p>Bogousslavsky J. On behalf of the European Stroke Initiative. Stroke prevention by the practitioner. Cerebrovasc Dis 1999;9(Suppl. 4):1-68.</p><p>Bonita R. Epidemiology of stroke. Lancet 1992;339:342-7.</p><p>Гусев Е.И. Скворцова В.И. Ишемия головного мозга. М.: Медицина, 2001;248 с.</p><p>Чуканова Е.И. Дисциркуляторная энцефалопатия (клиника, диагностика и лечение). Дис. … докт. мед. наук. М., 2004.</p><p>Goldstein L.B., Adams R., Becker K. et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2001;32:280-99.</p><p>Бойко А.Н., Камчатнов П.Р., Измаилов А.М. и др. Применение вазоактивных препаратов в комплексном лечении больных с хроническими расстройствами мозгового кровообращения. Методические рекомендации. М., 2005.</p><p>Шмидт Е.В. Классификация сосудистых поражений головного и спинного мозга. Журн невропатол и психиатр 1985;9:1281-8.</p><p>Kiss B., Karpati E. Mechanism of action of vinpocetine. Acta Pharm Hung 1996;66(5):213-24.</p><p>Kubota S., Ohmori S., Nagashima C. Experimental and clinical studies of cerebral blood flow in cerebrovascular disorders. In: Cytoprotection&Cytobiology. Nagao F. et al. (eds). Amsterdam: Excerpta Medica, 1987;4:164-72.</p><p>Ley Beth M. Vinpocetine: revitalize your brain with periwinkle extract. Detroit Lakes, MN: BL Publications, 2000;17.</p><p>Флетчер Р.И. Клиническая эпидемиология. Основы доказательной медицины. М., 1998;347 с.</p></div><br />
For citation:
Chukanova E.I., Chukanova E.I. Current aspects of the epidemiology and treatment of chronic brain ischemiain the presence of essential hypertension (results of the CALIPSO program). Neurology, Neuropsychiatry, Psychosomatics. 2011;3(1):38-42. (In Russ.) https://doi.org/10.14412/2074-2711-2011-132
Views: 469
Email this article 